Minerva Surgical

Minerva Surgical EBITDA per Share

The EBITDA per Share of Minerva Surgical (UTRS) as of Nov 3, 2026 is -3.30 USD. In the previous year, EBITDA per Share was -1.04 USD — a change of 215.56% (lower).

EBITDA per Share

-3.30USD

YoY

215.56%

Last updated:

EBITDA per Share of Minerva Surgical is 2023 -3.30 USD. EBITDA per Share of Minerva Surgical was 2022 -1.04 USD. It decreases by 215.56% lower compared to the previous year.

The Minerva Surgical EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-2.21 USD
Jan 1, 2020
-15.09 USD
Jan 1, 2021
-20.22 USD
Jan 1, 2022
-1.04 USD
Jan 1, 2023
-3.30 USD
The Minerva Surgical EBITDA per Share history
YEAREBITDA per ShareYoY
-3.30USD+215.56%
-1.04USD-94.83%
-20.22USD+34.04%
-15.09USD+581.76%
-2.21USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Minerva Surgical Stock analysis

What does Minerva Surgical do? Minerva Surgical, Inc. generates revenue through the commercialization of minimally invasive uterine healthcare solutions designed to treat abnormal uterine bleeding without necessitating hysterectomies. The company offers a suite of products targeting structural and non-structural causes of AUB, which are utilized by OB/GYNs in hospitals, ambulatory surgical centers, and physician offices. These devices address drawbacks of alternative treatments while preserving the uterus, appealing to healthcare providers seeking effective, non-invasive options for women's health. The firm's product line includes commercially available devices for minimally invasive alternatives to hysterectomy, specifically targeting the most common causes of AUB across various uterine anatomies. OB/GYNs across multiple medical settings purchase these solutions, leveraging their ability to address treatment limitations while avoiding unnecessary surgical interventions. The company's focus on preserving the uterus through non-hysterectomy methods differentiates its offerings in the women's health technology market. Minerva Surgical's revenue model relies on sales of its medical devices to healthcare providers, particularly OB/GYNs, who integrate the products into their treatment protocols for patients with abnormal uterine bleeding. The company's solutions are positioned as alternatives to traditional hysterectomy procedures, targeting a significant unmet need in women's healthcare. This approach allows the firm to capture market share by addressing both clinical and patient preference demands for less invasive care options. Minerva Surgical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Minerva Surgical stock

EBITDA per Share of Minerva Surgical is -3.30 USD in 2023.

EBITDA per Share of Minerva Surgical changed from -1.04 USD to -3.30 USD, representing a 215.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Minerva Surgical since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Minerva Surgical

All Key Metrics — Minerva Surgical